Heart Test Laboratories Stock Fundamentals
| HSCS Stock | USD 3.69 0.43 13.19% |
Fundamental analysis of Heart Test allows traders to better anticipate movements in Heart Test's stock price by examining its financial health and performance throughout various phases of its business cycle.
At this time, Heart Test's Depreciation And Amortization is comparatively stable compared to the past year. Total Revenue is likely to gain to about 20.5 K in 2025, whereas Interest Expense is likely to drop slightly above 242.9 K in 2025. Heart | Select Account or Indicator | Build AI portfolio with Heart Stock |
Heart Test Laboratories Company Current Valuation Analysis
Heart Test's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Heart Test Current Valuation | 3.91 M |
Most of Heart Test's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Heart Test Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Heart Test Laboratories has a Current Valuation of 3.91 M. This is 99.97% lower than that of the Health Care Equipment & Supplies sector and 99.97% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Heart Test Laboratories Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Heart Test's current stock value. Our valuation model uses many indicators to compare Heart Test value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Heart Test competition to find correlations between indicators driving Heart Test's intrinsic value. More Info.Heart Test Laboratories is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Heart Test's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Heart Test by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Heart Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Heart Test's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Heart Test could also be used in its relative valuation, which is a method of valuing Heart Test by comparing valuation metrics of similar companies.Heart Test is currently under evaluation in current valuation category among its peers.
Heart Test ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Heart Test's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Heart Test's managers, analysts, and investors.Environmental | Governance | Social |
Heart Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 3.91 M | ||||
| Shares Outstanding | 1.08 M | ||||
| Shares Owned By Insiders | 8.99 % | ||||
| Shares Owned By Institutions | 2.17 % | ||||
| Number Of Shares Shorted | 9.04 K | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 202.07 X | ||||
| Revenue | 18.6 K | ||||
| EBITDA | (6.16 M) | ||||
| Net Income | (6.61 M) | ||||
| Cash And Equivalents | 4.27 M | ||||
| Cash Per Share | 0.52 X | ||||
| Total Debt | 1.04 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 3.53 X | ||||
| Book Value Per Share | 1.73 X | ||||
| Cash Flow From Operations | (6.07 M) | ||||
| Short Ratio | 0.62 X | ||||
| Earnings Per Share | (7.61) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 15 | ||||
| Beta | 2.63 | ||||
| Market Capitalization | 3.52 M | ||||
| Total Asset | 9.5 M | ||||
| Retained Earnings | (67.36 M) | ||||
| Working Capital | 5.6 M | ||||
| Net Asset | 9.5 M |
About Heart Test Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heart Test Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heart Test using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heart Test Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 767.2 K | 563.6 K | |
| Total Revenue | 16.7 K | 20.5 K | |
| Cost Of Revenue | 5.5 K | 5.2 K | |
| Stock Based Compensation To Revenue | 19.60 | 12.45 | |
| Research And Ddevelopement To Revenue | 139.28 | 150.39 | |
| Capex To Revenue | 6.06 | 6.36 | |
| Revenue Per Share | 0.06 | 0.06 | |
| Ebit Per Revenue | (389.87) | (409.37) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.